

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 7, 2017

Adam Craig President and Chief Executive Officer CTI BioPharma Corporation 3101 Western Avenue, Suite 600 Seattle, Washington 98121

> Re: CTI BioPharma Corporation Preliminary Proxy Statement on Schedule 14A Filed November 28, 2017 File No. 000-28386

Dear Dr. Craig:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Brophy Christensen - O'Melveny & Myers LLP